




RealRate

PHARMACEUTICAL 2014

Tobira Therapeutics Inc
Rank 115 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Tobira Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tobira Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 85% points. The greatest weakness of Tobira Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 263%, being 20% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	39,128
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,100
Liabilities, Non-Current	2,452
Other Assets	6,517
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-600
Other Revenues	832
Property and Equipment	108
Research and Development	26,542
Selling, General and Administrative Expense	7,297

Output Variable	Value in 1000 USD
Assets	45,753
Liabilities	11,552
Expenses	33,839
Revenues	832
Stockholders Equity	34,201
Net Income	-33,607
Comprehensive Net Income	-33,607
BaseVar	46,288
ECR before LimitedLiability	143%
Economic Capital Ratio	263%